NCT02903667 (Biomaterial) is a Phase 4 clinical trial of Bone grafting in Alveolar Ridge Trauma, sponsored by Institute Franci.

Who is sponsoring NCT02903667?

NCT02903667 is sponsored by Institute Franci.

What drugs are being tested in NCT02903667?

Interventions in NCT02903667: Bone grafting.

What condition does NCT02903667 study?

NCT02903667 studies Alveolar Ridge Trauma, Bone Resorption.

Is NCT02903667 still recruiting?

NCT02903667 is currently completed. Last updated 16 November 2025.

Last reviewed 2025-11-16 · How we verify

NCT02903667: Biomaterial

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomaterial to Counteract Ridge Reduction Following the Removal of Multiple Adjacent Teeth. A Prospective Randomized Controlled Study.

Completed Phase 4 Last updated 16 November 2025

What this trial tests

Phase 4 trial testing Bone grafting in Alveolar Ridge Trauma in 40 participants. Completed in 1 September 2023.

Timeline

1 March 2015

Primary endpoint
1 September 2023

1 September 2023

Quick facts

Lead sponsor	Institute Franci
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 March 2015
Primary completion	1 September 2023
Estimated completion	1 September 2023
Sites	1 location across Italy

Drugs / interventions tested

Bone grafting — full drug profile →

Conditions studied

Alveolar Ridge Trauma — all drugs for Alveolar Ridge Trauma →
Bone Resorption — all drugs for Bone Resorption →

Sponsor

Institute Franci

Who can join

25 and older, any sex, with Alveolar Ridge Trauma or Bone Resorption. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Cone Beam Computerized Tomographic (CBCT) examination at the center of each extraction socket, between the sockets, at the septum next to adjacent teeth.
Time frame: Up to 24 weeks
Measurements of alveolar ridge dimensional changes in the first 6 months of healing

Sponsor's own description

An open, prospective, randomized, multicenter study focused on the ridge diminution in case of grafting of fresh extraction sockets with Bio-Oss Collagen, Bio-Gide (Geistlich Pharma, Wolhusen, Switzerland), placing Dentsply implants (Astra Tech System).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Bone grafting

Trials testing the same drug.

NCT07104370 — Freeze-dried Bone Allograft vs Autologous Bone Blocks in the Lateral Augmentation of the Jaws · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02903667 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute Franci
Last refreshed: 16 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02903667.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing